Literature DB >> 16973567

The negative regulator of splicing element of Rous sarcoma virus promotes polyadenylation.

Jeremy E Wilusz1, Karen L Beemon.   

Abstract

The Rous sarcoma virus gag gene contains a cis-acting negative regulator of splicing (NRS) element that is implicated in viral polyadenylation regulation. To study the mechanism of polyadenylation promotion at the viral poly(A) site located over 8 kb downstream, we performed in vitro polyadenylation analysis. RNA containing only the poly(A) site and flanking sequences in the 3' long terminal repeat (LTR) was not polyadenylated detectably in vitro; however, if the transcript contained the NRS upstream of the LTR, polyadenylation was observed. Insertion of the viral env 3' splice site sequence between the NRS and the LTR did not alter the level of polyadenylation appreciably. We conclude that the NRS promotes polyadenylation in vitro and can do so without formation of a splicing complex with a 3' splice site. We then explored the roles of several cellular factors in NRS-mediated polyadenylation. Mutation of the binding sites of U1 and U11 snRNPs to the NRS did not affect polyadenylation, whereas hnRNP H strongly inhibited polyadenylation. We propose a model in which hnRNP H and SR proteins compete for binding to the NRS. Bound SR proteins may bridge between the NRS and the 3' LTR and aid in the recruitment of the 3'-end processing machinery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973567      PMCID: PMC1617230          DOI: 10.1128/JVI.00845-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Two distant upstream regions containing cis-acting signals regulating splicing facilitate 3'-end processing of avian sarcoma virus RNA.

Authors:  J T Miller; C M Stoltzfus
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Solution structure of the pseudo-5' splice site of a retroviral splicing suppressor.

Authors:  Javier Cabello-Villegas; Keith E Giles; Ana Maria Soto; Ping Yu; Annie Mougin; Karen L Beemon; Yun-Xing Wang
Journal:  RNA       Date:  2004-09       Impact factor: 4.942

3.  In vitro polyadenylation is stimulated by the presence of an upstream intron.

Authors:  M Niwa; S D Rose; S M Berget
Journal:  Genes Dev       Date:  1990-09       Impact factor: 11.361

4.  Proposed gag-encoded transcriptional activator is not necessary for Rous sarcoma virus replication or transformation.

Authors:  K Carlberg; K Beemon
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  A 64 kd nuclear protein binds to RNA segments that include the AAUAAA polyadenylation motif.

Authors:  J Wilusz; T Shenk
Journal:  Cell       Date:  1988-01-29       Impact factor: 41.582

6.  Mutation of an RSV intronic element abolishes both U11/U12 snRNP binding and negative regulation of splicing.

Authors:  R R Gontarek; M T McNally; K Beemon
Journal:  Genes Dev       Date:  1993-10       Impact factor: 11.361

Review 7.  Transcription termination and polyadenylation in retroviruses.

Authors:  R V Guntaka
Journal:  Microbiol Rev       Date:  1993-09

8.  SR protein splicing factors interact with the Rous sarcoma virus negative regulator of splicing element.

Authors:  L M McNally; M T McNally
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Regulation of Rous sarcoma virus RNA splicing and stability.

Authors:  S Arrigo; K Beemon
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

10.  Upstream introns influence the efficiency of final intron removal and RNA 3'-end formation.

Authors:  D Nesic; L E Maquat
Journal:  Genes Dev       Date:  1994-02-01       Impact factor: 11.361

View more
  16 in total

1.  Serine/arginine-rich proteins contribute to negative regulator of splicing element-stimulated polyadenylation in rous sarcoma virus.

Authors:  Nicole L Maciolek; Mark T McNally
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

Review 2.  RNA processing control in avian retroviruses.

Authors:  Mark T McNally
Journal:  Front Biosci       Date:  2008-05-01

Review 3.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

4.  An LYPSL late domain in the gag protein contributes to the efficient release and replication of Rous sarcoma virus.

Authors:  Kari A Dilley; Devon Gregory; Marc C Johnson; Volker M Vogt
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

5.  Nucleophosmin deposition during mRNA 3' end processing influences poly(A) tail length.

Authors:  Fumihiko Sagawa; Hend Ibrahim; Angela L Morrison; Carol J Wilusz; Jeffrey Wilusz
Journal:  EMBO J       Date:  2011-08-05       Impact factor: 11.598

6.  Evidence that a threshold of serine/arginine-rich (SR) proteins recruits CFIm to promote rous sarcoma virus mRNA 3' end formation.

Authors:  Stephen W Hudson; Lisa M McNally; Mark T McNally
Journal:  Virology       Date:  2016-09-04       Impact factor: 3.616

7.  Juxtaposition of two distant, serine-arginine-rich protein-binding elements is required for optimal polyadenylation in Rous sarcoma virus.

Authors:  Stephen W Hudson; Mark T McNally
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

8.  Characterization of Rous sarcoma virus polyadenylation site use in vitro.

Authors:  Nicole L Maciolek; Mark T McNally
Journal:  Virology       Date:  2008-02-13       Impact factor: 3.616

9.  Polyadenylation site choice in yeast is affected by competition between Npl3 and polyadenylation factor CFI.

Authors:  Miriam E Bucheli; Xiaoyuan He; Craig D Kaplan; Claire L Moore; Stephen Buratowski
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

Review 10.  Molecular mechanisms of eukaryotic pre-mRNA 3' end processing regulation.

Authors:  Stefania Millevoi; Stéphan Vagner
Journal:  Nucleic Acids Res       Date:  2009-12-30       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.